Ouch! Pfizer terminates S. aureus vaccine trial due futility (Part 3 of 3)
Addendum: This is the third in a 3-newsletters series on this topic. I need to do a specific newsletter on the challenges of vaccines but
20 December 2018
No Comments
R&D Insight
FDA AMDAC (26 April 2019) on IM Bacitracin for pneumonia in infants: Follow-up note
Addendum: This is the third in a series of newsletters on IM bacitracin. Go here for the prior newsletter and here for the 4th and
1 May 2019
No Comments
Duration of antibiotic dosing in veterinary medicine / Follow-up comment on FDA AMDAC on IM Bacitracin
Addendum: This is the second in a series of newsletters on IM bacitracin. Go here for the prior newsletter and here for the next newsletter.
1 April 2019
No Comments
FDA Antimicrobial Drugs Advisory Committee (AMDAC) on 26 Apr 2019: IM Bacitracin for staphylococcal pneumonia and empyema in infants?!
Addendum: This is the first of a series of newsletters on IM bacitracin. Go here for the next newsletter. Dear All: FDA has announced that on 26
25 March 2019
No Comments
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
Dear All (detailed and wonkish note alert … lots of thinking out loud … get some coffee and settle in!), I wrote previously (link) about
8 March 2020
No Comments
What does an antibiotic cost to develop? What is it worth? How to afford it?
Dear All (long, wonkish note alert!): Today we have a 3-part discussion of cost and value with this summary 3-part message: Developing antibiotics is expensive,
6 March 2020
No Comments
COVID-19 R&D support: US (FDA, BARDA, NIAID), Europe (EMA, EC), and globally (BioCentury resource hub)
Dear All, And now for a change from our usually scheduled content! As you might expect, major agencies in the US (FDA, BARDA, NIAID) and
16 April 2020
No Comments
Glaxo seeks buyer for two of its older antibiotics / AMR podcasts to share
Heads-up … numerous changes in the meeting calendar: Lots of new events as well as rescheduling of previously announced events. Dear All, A busy start
3 March 2020
No Comments
Global AMR Hub launches Incentives Gallery / AMR Conference is underway
Dear All, In case you missed it, the 4th AMR Conference sponsored by BEAM, CARB-X, Novo REPAIR, Wellcome Trust, the UK, and many others (link)
25 August 2020
No Comments
Estimating attributable mortality of resistant bloodstream infections: GLASS (WHO) recommended method
Dear All, WHO’s GLASS Secretariat (Global Antimicrobial Resistance Surveillance System, link) have recently released a standardized method for estimating attributable mortality of antimicrobial resistant bloodstream
20 July 2020
No Comments